Compare OFIX & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFIX | MYGN |
|---|---|---|
| Founded | 1987 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.0M | 444.2M |
| IPO Year | 1998 | 1996 |
| Metric | OFIX | MYGN |
|---|---|---|
| Price | $9.76 | $3.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $17.25 | $7.64 |
| AVG Volume (30 Days) | 338.4K | ★ 2.7M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $822,312,000.00 | $771,400,000.00 |
| Revenue This Year | $6.13 | $6.86 |
| Revenue Next Year | $6.22 | $5.45 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.85 | 2.33 |
| 52 Week Low | $8.85 | $2.74 |
| 52 Week High | $16.99 | $8.59 |
| Indicator | OFIX | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 38.10 | 37.18 |
| Support Level | $8.99 | $2.79 |
| Resistance Level | $9.90 | $3.31 |
| Average True Range (ATR) | 0.38 | 0.16 |
| MACD | -0.08 | 0.08 |
| Stochastic Oscillator | 16.10 | 64.13 |
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.